Get the Stockscreener App
6.82
1.04%
0.07
After Hours:
6.90
0.08
+1.17%
Tango Therapeutics Inc stock is traded at $6.82, with a volume of 1.29M.
It is up +1.04% in the last 24 hours and up +37.22% over the past month.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
See More
Previous Close:
$6.75
Open:
$6.74
24h Volume:
1.29M
Relative Volume:
0.46
Market Cap:
$739.25M
Revenue:
$42.51M
Net Income/Loss:
$-116.49M
P/E Ratio:
-6.0893
EPS:
-1.12
Net Cash Flow:
$-120.82M
1W Performance:
+0.74%
1M Performance:
+37.22%
6M Performance:
+124.34%
1Y Performance:
-30.76%
1-Day Range:
$6.68
$7.105
1-Week Range:
$6.36
$7.105
52-Week Range:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Name
Tango Therapeutics Inc
Sector
Industry
Phone
(857) 320-4900
Address
201 BROOKLINE AVENUE, BOSTON
Compare TNGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.82 | 731.66M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-17-24 | Initiated | Jefferies | Buy |
| Apr-04-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-24 | Initiated | Piper Sandler | Overweight |
| Dec-08-23 | Initiated | B. Riley Securities | Buy |
| Oct-20-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-20-21 | Initiated | SVB Leerink | Outperform |
View All
Tango Therapeutics Inc Stock (TNGX) Latest News
What drives Tango Therapeutics Inc. stock priceMassive portfolio appreciation - Autocar Professional
Will Tango Therapeutics Inc. stock benefit from AI tech trendsSuperior capital gains - jammulinksnews.com
Is Tango Therapeutics Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
What analysts say about Tango Therapeutics Inc. stockExplosive portfolio gains - Autocar Professional
Tango Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Optimistic Investors Push Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Up 31% But Growth Is Lacking - 富途牛牛
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire
Tango Therapeutics Earnings Alert: Q2 2025 Results Coming August 5 Without Investor Call - Stock Titan
Will Tango Therapeutics Inc. stock benefit from interest rate changesMarket Timing Advice - Newser
How Tango Therapeutics Inc. stock performs during market volatilityFree Consultation - Newser
How high can Tango Therapeutics Inc. stock price go in 2025Daily Volume Leaders - Newser
Can Tango Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect? - MSN
What makes Tango Therapeutics Inc. stock price move sharplySolid Return Trade Selections - Newser
Why Tango Therapeutics Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
Tango Therapeutics (TNGX) Soars 5.96% on Strong Q2 Earnings - AInvest
Tango Therapeutics’ SWOT analysis: biotech stock’s potential in precision cancer therapies - Investing.com Nigeria
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - MSN
HC Wainwright Issues Optimistic Forecast for TNGX Earnings - Defense World
Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Value Index - MarketScreener
H.C. Wainwright reiterates Buy rating on Tango Therapeutics stock - Investing.com
Tango Therapeutics Inc Stock (TNGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):